Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Bobin

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Bulletin Du Cancer|December 16, 2025
[Isatuximab, bortezomib, lenalidomide and dexamethasone - Newly diagnosed transplant-ineligible multiple myeloma]Aurélien Pichon, Arthur Bobin
Blood|February 27, 2025
Novel interferon-based antimyeloma activityArthur Bobin, Xavier Leleu
Faculty Reviews|October 13, 2022
Recent advances in the treatment of multiple myeloma: a brief reviewArthur Bobin, Xavier Leleu
Bulletin Du Cancer|August 6, 2022
[New drug approval: Ciltacabtagene autoleucel - in patients with relapsed or refractory multiple myeloma who received 3 or more lines of therapy]Aurélia Chacon, Arthur Bobin, Xavier Leleu
Cancers|April 13, 2023
30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple MyelomaAurelia Chacon, Xavier Leleu, Arthur Bobin
Leukemia|April 24, 2025
Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myelomaXavier Leleu, Arthur Bobin, Andre Herbelin, et al.
Med (New York, N.Y.)|June 12, 2026
Five trials reshaping multiple myelomaAlexis Talbot, Arthur Bobin, Cyrille Touzeau, et al.
Leukemia Research Reports|January 23, 2024
Posterior reversible encephalopathy syndrome (PRES) and myelomaRicardos Ghanem, Sylvie Glaisner, Arthur Bobin, et al.
Frontiers in Oncology|May 22, 2020
The Role of Immunotherapy in Non-transplant Eligible Multiple MyelomaArthur Bobin, Hélène Gardeney, Florence Sabirou, et al.
British Journal of Haematology|May 15, 2023
Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasmsThomas Systchenko, Jean-Claude Chomel, Pilar Gallego-Hernanz, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Bulletin Du Cancer|December 16, 2025
[Isatuximab, bortezomib, lenalidomide and dexamethasone - Newly diagnosed transplant-ineligible multiple myeloma]Aurélien Pichon, Arthur Bobin
Blood|February 27, 2025
Novel interferon-based antimyeloma activityArthur Bobin, Xavier Leleu
Faculty Reviews|October 13, 2022
Recent advances in the treatment of multiple myeloma: a brief reviewArthur Bobin, Xavier Leleu
Bulletin Du Cancer|August 6, 2022
[New drug approval: Ciltacabtagene autoleucel - in patients with relapsed or refractory multiple myeloma who received 3 or more lines of therapy]Aurélia Chacon, Arthur Bobin, Xavier Leleu
Cancers|April 13, 2023
30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple MyelomaAurelia Chacon, Xavier Leleu, Arthur Bobin
Leukemia|April 24, 2025
Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myelomaXavier Leleu, Arthur Bobin, Andre Herbelin, et al.
Med (New York, N.Y.)|June 12, 2026
Five trials reshaping multiple myelomaAlexis Talbot, Arthur Bobin, Cyrille Touzeau, et al.
Leukemia Research Reports|January 23, 2024
Posterior reversible encephalopathy syndrome (PRES) and myelomaRicardos Ghanem, Sylvie Glaisner, Arthur Bobin, et al.
Frontiers in Oncology|May 22, 2020
The Role of Immunotherapy in Non-transplant Eligible Multiple MyelomaArthur Bobin, Hélène Gardeney, Florence Sabirou, et al.
British Journal of Haematology|May 15, 2023
Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasmsThomas Systchenko, Jean-Claude Chomel, Pilar Gallego-Hernanz, et al.
Pageof 5